Osteoporosis: Pathogenesis, diagnosis, and treatment in older adults

Rheumatic Disease Clinics of North America

Volumn 26, Issue 3, 2000, Pages 569-591

  Kenny, Anne M ^b   Prestwood, Karen M ^b  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; ESTROGEN; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SEX HORMONE; VITAMIN D;

BONE DENSITY; BONE MASS; BONE MINERAL; BONE TURNOVER; CALCIUM DEFICIENCY; DIET SUPPLEMENTATION; DISABILITY; ESTROGEN THERAPY; HEALTH CARE COST; HIP FRACTURE; HORMONE DEFICIENCY; MENOPAUSE; MORTALITY; OSTEOLYSIS; OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW; SCORING SYSTEM; SECONDARY HYPERPARATHYROIDISM; VERTEBRA FRACTURE;

EID: 0033845257     PISSN: 0889857X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-857X(05)70157-5     Document Type: Article

References (142)

1. IL-1β and IL-1RA gene expression in transiliac bone biopsies: Correlation with bone loss and histomorphometry in healthy postmenopausal women
2. Intermittent etidronate therapy to prevent corticosteroid induced osteoporosis
3. Androgen supplementation in eugonadal men with osteoporosis: Effects of six months' treatment on markers of bone formation and resorption
4. ACSM position stand on osteoporosis and exercise. American College of Sports Medicine
5. Effects of hormone replacement therapy on endometiral histology in postmenopausal women: The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial: The Writing Group for the PEPI Trial
6. The significance of lacunar erosion without osteoclastis: Studies on the reversal phase of the remodeling sequence
7. Effect of oral calcium and vitamin D on glucocorticoid-induced osteopenia
8. Increased cytokine secretion by human bone marrow cells after menopause or discontinuation of estrogen replacement
9. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures: Fracture Intervention Trial Research Group
10. Osteoporosis Study Centers: Dose-response relationships for alendronate treatment in osteoporotic elderly women
11. Calciotropic hormones and markers of bone remodeling in age-related (type II) femoral neck osteoporosis: Alterations consistent with secondary hyperparathyroidism-induced bone resorption
12. Risk factors for increased bone loss in an elderly population: The Rotterdam Study
13. Growth factors and the regulation of bone remodeling
14. Effect of oestrogen replacement on bone metabolism and cytokines in surgical menopause
15. Bone mineral density and risk of breast cancer in older women: The study of osteoporotic fractures: Study of osteoporotic fractures research group
16. Estrogen replacement therapy and fractures in older women: Study of osteoporotic fractures research group
17. Vitamin D3 and calcium to prevent hip fractures in elderly women
18. Production of various cytokines by normal human osteoblast-like cells in response to interleukin-1β and tumor necrosis factor-α: Lack of regulation by 17β-estradiol
19. Hormone replacement therapy in postmenopausal women: Urinary N-telopeptide of type I collagen monitors therapeutic effect and predicts response of bone mineral density
20. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women
21. A new probable increasing cause of esophageal ulceration: Alendronate
22. Diagnosis, prophylaxis and treatment of osteoporosis
23. Can we improve compliance of long-term hormone replacement therapy?
24. Increase in clinically diagnosed vertebral fractures: A population based study in Rochester, MN
25. Estrogen protection against bone resorbing effects of parathyroid hormone infusion
26. Alendronate reduces the risk of vertebral fractures in women without pre-existing vertebral fractures: Results of the fracture intervention trial
27. The effect of raloxifene on risk of breast cancer in postmenopausal women
28. Epidemiology of osteoporosis and osteoporotic fractures
29. Risk factors for hip fracture in white women: Study of Osteoporotic Fractures Research Group
30. A controlled trial of the effect of calcium supplementation on bone density in postmenopausal women
31. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older
32. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women
33. Biologic basis for interleukin-1 in disease
34. Effect of oral 1,25-dihydroxyvitamin D and calcium on glucocorticoid-induced osteopenia in patients with rheumatic disease
35. Calcium supplementation reduces vertebral bone loss in perimenopausal women: A controlled trial in 248 women between 46 and 55 years of age
36. The effect f2 and 3 years of raloxifene on vertebral and non-vertebral fractures in postmenopausal women with osteoporosis
37. Increases in bone density during treatment of men with idiopathic hypogonadotropic hypogonadism
38. Osteoporosis in men with idiopathic hypogonadotropic hypogonadism
39. Osteopenia in men with a history of delayed puberty
40. Differences in the time course of the effects of oophorectomy in women on parameters of bone metabolism and interleukin-1 levels in the circulation
41. Effect of age on circulating immunoreactive and bioactive parathyroid hormone levels in women
42. Intestinal calcium absorption and serum vitamin D metabolites in normal subjects and osteoporotic patients: Effect of age and dietary calcium
43. Markers of bone resorption predict hip fracture in elderly women: The EPIDOS prospective study
44. Increased bone turnover in late postmenopausal women is a major determinat of osteoporosis
45. Lifetime leisure exercise and osteoporosis: The Rancho Bernardo study
46. Femoral bone loss progresses with age: A longitudinal study in women over age 65
47. Importance of gonadal steroids to bone mass in men with hyperprolactinemic hypogonadism
48. Bone mineral density in elderly men and women: Results from the Framingham osteoporosis study
49. An 18-year prospective study of dietary calcium and bone mineral density in the hip
50. Cytokines and estrogen in bone: Anti-osteoporotic effects
51. Alendronate in the prevention of osteoporosis: EPIC study two-year results
52. Estrogen promotes apoptosis of murine osteoclasts mediated by TGF-beta
53. Bone histomorphometry in hypogonadal and eugonadal men with spinal osteoporosis
54. Testosterone deficiency as a risk factor for hip fracture in men: A case control study
55. Therapeutic strategies in the prevention of hip fracture with drugs affecting bone metabolism
56. Life-style and different fracture prevalence: A cross sectional comparative population-based study
57. Cytokine production in the bone marrow microenvironment: Failure to demonstrate estrogen regulation in early postmenopausal women
58. Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism
59. Ovariectomy enhances and estrogen replacement inhibits the activity of bone marrow factors that stimulate prostaglandin production in cultured mouse calvariae
60. Dietary calcium, sex hormones, and bone mineral density in men
61. The effects of transdermal testosterone on bone mineral density, bone turnover markers and muscle strength in older men
62. Bone turnover, bone mineral density, and muscle strength in healthy older men with low testosterone levels
63. Circulating cytokine levels in osteoporotic and normal women
64. Serum insulin-like growth factor binding protein profiles in post-menopausal women: Their correlation with bone mineral density
65. Bisphosphonate therapy
66. Effect of oral alendronate on bone density and the incidence of fractures in postmenopausal osteoporosis
67. Therapeutic controversy: Estrogen replacement in menopause
68. Effect of alendronate added to ongoing hormone replacement therapy on the bone mineral density in women with postmenopausal osteoporosis
69. Mice deficient in the functional interleukin-1 receptor I (IL-1R1) do not lose bone mass after ovariectomy
70. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer
71. Treatment of established postmenopausal osteoporosis with raloxifene: A randomized trial
72. Association of osteoporotic vertebral compression fractures with impaired functional status
73. Analgesic effect of salmon calcitonin in osteoporotic vertebral fractures: A double-blind placebo-controlled clinical study
74. Predictors of functional recovery one year following hospital discharge for hip fracture: A prospective study
75. Bone marrow, cytokines, and bone remodeling: Emerging insights into the pathophysiology of osteoporosis
76. In vitro production of cytokines by bone surface-derived osteoblastic cells in normal and osteoporotic postmenopausal women: Relationship with cell proliferation
77. On aging bone
78. Bone density and fracture risk in men
79. Epidemiology of age-related fractures
80. Prevention of corticosteroid-induced osteoporosis with salmon calcitonin in sarcoid patients
81. Effects of testosterone replacement therapy in old hypogonadal males: A preliminary study
82. Sex differences in age-related changes in vertebral body size, density and biomechanical competence in normal individuals
83. Bone loss in elderly women by ultralow doses of parenteral 17β estradiol
84. Effects of high-intensity strength training on multiple risk factors for osteoporotic fractures: A randomized controlled trial
85. Optimal calcium intake: NIH consensus development panel on optimal calcium intake
86. Assessment of sex hormones and bone mineral density in relation to occurrence of fracture in men: A prospective population-based study
87. The rate of bone mineral loss in normal men and the effects of calcium and cholecalciferol supplementation
88. Discontinuous calcitonin treatment of established osteoporosis-effects of withdrawal of treatment
89. Effect of surgical menopause and estrogen replacement on cytokine release from human blood mononuclear cells
90. Ovarian steroid treatment blocks a postmenopausal increase in blood monocyte interleukin 1 release
91. Monocytic secretion of interleukin-1 receptor antagonist in normal and osteoporotic women: Effects of menopause and estrogen/ progesterone therapy
92. Estrogen, cytokines, and pathogenesis of postmenopausal osteoporosis
93. Exercise and other factors in the prevention of hip fracture: The leisure world study
94. Relationships between surface, volume, and thickness of iliac trabecular bone in aging and in osteoporosis: Implications for the microanatomic and cellular mechanisms of bone
95. Estrogen and calcium have an additive effect on bone turnover in older women
96. The short-term effects of conjugated estrogen on bone turnover in older women
97. Low dose conjugated estrogen reduces biochemical markers of bone turnover in older women
98. The effects of calcium supplementation (milk powder or tablets) and exercise on bone density in postmenopausal women
99. Osteoporosis
100. Analysis of gene expression in human bone biopsies by polymerase chain reaction: Evidence for enhanced cytokine expression in postmenopausal osteoporosis
101. The effect of low-dose continuous estrogen and progesterone therapy with calcium and vitamin D on bone in elderly women: A randomized, controlled trial
102. Effect of calcium supplementation on bone loss in postmenopausal women
103. Testosterone therapy in glucocorticoid-treated men
104. Production of interleukin-6 in human osteoblasts and human bone marrow stromal cells: Evidence that induction by interleukin-1 and tumor necrosis factor-α is not regulated by ovarian steroids
105. A unitary model for involutional osteoporosis: Estrogen deficiency causes both Type I and Type II osteoporosis in postmenopausal women and contributes to bone loss in aging men
106. The worldwide problem of osteoporosis: Insights afforded by epidemiology
107. Involutional osteoporosis
108. The prevention and treatment of osteoporosis
109. Changes in bone mineral density of the proximal femur and spine with aging
110. The relative contribution of trabecular and cortical bone to the strength of human lumbar vertebrae
111. The predictive value of biochemical markers of bone turnover for bone mineral density in early postmenopausal women treated with hormone replacement or calcium supplementation
112. Skeletal alkaline phosphatase (Tandem(C)-R Ostase(C)) measurements predict rapid bone loss during 13 years follow up
113. Effects of alendronate for two years on BMD and fractures in patients receiving glucocorticoids
114. Prevention of corticosteroid osteoporosis: A comparison of calcium, calcitriol and calcitonin
115. Timing of postmenopausal estrogen for optimal bone mineral density: The Rancho Bernardo Study
116. Risk factors for spinal osteoporosis in men
117. Calcitonin
118. Long-term bone loss in men: Effects of genetic and environmental factors
119. Changes in plasma steroids and bone density in Kleinfelter's syndrome
120. Estrogen resistance caused by a mutation in the estrogen receptor gene in a man
121. Effects of testosterone treatment on bone mineral density in men over 65
122. Esophageal ulceration due to alendronate
123. The comparative effect on bone density, endometirum, and lipids of continuous hormones as replacement therapy
124. Does hypogonadism contribute to the occurrence of a minimal trauma hip fracture in elderly men?
125. Castrated men exhibit bone loss: Effect of calcitonin treatment on biochemical indices of bone remodeling
126. Calcitonin salmon nasal spray reduces the incidence of new vertebral fractures in postmenopausal women: Three year interim results of the PROOF study (abstract)
127. Effects of estrogen in vivo and in vitro on spontaneous interleukin-1 release by monocytes from postmenopausal women
128. Five years of clinical experience with intermittent cyclical etidronate for postmenopausal osteoporosis
129. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis
130. Effects of testosterone supplementation in the aging male
131. Effects of hormone replacement therapy on bone mineral density: Results from the Postmenopausal Estrogen/Progestin Intervention Trials (PEPI)
132. Sublingual testosterone replacement improves muscle mass and strength, decreases bone resorption, and increases bone formation markers in hypogonadal men: A clinical research center study
133. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis
134. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis
135. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL
136. The murine mutation osteopetrosis is in the coding region of the macrophage colonly stimulating factor gene